13 research outputs found
Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies
Bevacizumab (antivascular endothelial growth factor [anti-VEGF]) and cetuximab (antiepidermal growth factor receptor [anti-EGFR]) are approved antibodies for treatment of cancer. However, in advanced colorectal cancer, the combination fails to improve survival. As the reason for the lack of activity is unknown, our study aims to determine the effect of bevacizumab on targeting of anti-EGFR and insulin-like growth factor 1 receptor (IGF-1R) antibodies in tumors with single-photon emission computed tomography (SPECT)/CT imaging. Mice with subcutaneous EGFR and IGF-1R-expressing SUM149 xenografts received a single dose of bevacizumab (10 mg/kg) or saline. After 4 days, mice were injected with radiolabeled cetuximab or R1507, an anti-IGF-1R antibody. A control group received a radiolabeled irrelevant IgG (hLL2). Three days later, SPECT/CT images were acquired and mice were dissected to determine the concentration of antibodies in the tissues. Tumors were analyzed immunohistochemically to determine vascular density (CD34), VEGF, EGFR and IGF-1R expression. SPECT/CT imaging revealed that bevacizumab treatment significantly reduced tumor targeting of radiolabeled cetuximab by 40% from 33.1 +/- 1.1 %ID/g to 19.8 +/- 5.7 %ID/g (p=0.009) for untreated and bevacizumab-treated tumors, respectively. A similar effect was found for 111In-R1507: tumor targeting of R1507 decreased by 35%. No significant differences in tumor uptake were observed in mice that received an irrelevant IgG. Uptake in normal organs was not altered by bevacizumab. Immunohistochemical analysis showed that vascular density decreased with 43%, whereas EGFR and IGF-1R expression was unaltered. In conclusion, bevacizumab treatment significantly reduces tumor targeting of anti-EGFR and anti-IGF-1R antibodies. This emphasizes the importance of timing and sequencing of bevacizumab in combination with other antibodie
A Clinical Feasibility Study To Image Angiogenesis in Patients With Arteriovenous Malformations Using 68Ga-RGD PET/CT
Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents
BACKGROUND: While immune checkpoint inhibitors such as anti-PD-L1 antibodies have revolutionized cancer treatment, only subgroups of patients show durable responses. Insight in the relation between clinical response, PD-L1 expression and intratumoral localization of PD-L1 therapeutics could improve patient stratification. Therefore, we present the modular synthesis of multimodal antibody-based imaging tools for multiscale imaging of PD-L1 to study intratumoral distribution of PD-L1 therapeutics. RESULTS: To introduce imaging modalities, a peptide containing a near-infrared dye (sulfo-Cy5), a chelator (DTPA), an azide, and a sortase-recognition motif was synthesized. This peptide and a non-fluorescent intermediate were used for site-specific functionalization of c-terminally sortaggable mouse IgG1 (mIgG1) and Fab anti-PD-L1. To increase the half-life of the Fab fragment, a 20Â kDa PEG chain was attached via strain-promoted azide-alkyne cycloaddition (SPAAC). Biodistribution and imaging studies were performed with (111)In-labeled constructs in 4T1 tumor-bearing mice. Comparing our site-specific antibody-conjugates with randomly conjugated antibodies, we found that antibody clone, isotype and method of DTPA conjugation did not change tumor uptake. Furthermore, addition of sulfo-Cy5 did not affect the biodistribution. PEGylated Fab fragment displayed a significantly longer half-life compared to unPEGylated Fab and demonstrated the highest overall tumor uptake of all constructs. PD-L1 in tumors was clearly visualized by SPECT/CT, as well as whole body fluorescence imaging. Immunohistochemistry staining of tumor sections demonstrated that PD-L1 co-localized with the fluorescent and autoradiographic signal. Intratumoral localization of the imaging agent could be determined with cellular resolution using fluorescent microscopy. CONCLUSIONS: A set of molecularly defined multimodal antibody-based PD-L1 imaging agents were synthesized and validated for multiscale monitoring of PD-L1 expression and localization. Our modular approach for site-specific functionalization could easily be adapted to other targets. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01272-5
A Clinical Feasibility Study To Image Angiogenesis in Patients With Arteriovenous Malformations Using Ga-RGD PET/CT.
Arteriovenous malformations (AVMs) have an inherent capacity to form new blood vessels, resulting in excessive lesion growth, and this process is further triggered by the release of angiogenic factors. 68Ga-labeled arginine-glycine-aspartate tripeptide sequence (RGD) PET/CT imaging may provide insight into the angiogenic status and treatment response of AVMs. This clinical feasibility study was performed to demonstrate that 68Ga-RGD PET/CT imaging can be used to quantitatively assess angiogenesis in peripheral AVMs. METHODS: Ten patients with a peripheral AVM (mean age, 40 y; 4 men and 6 women) and scheduled for endovascular embolization treatment were prospectively included. All patients underwent 68Ga-RGD PET/CT imaging 60 min after injection (mean dose, 207 ± 5 MBq). Uptake in the AVM, blood pool, and muscle was quantified as SUVmax and SUVpeak, and a descriptive analysis of the PET/CT images was performed. Furthermore, immunohistochemical analysis was performed on surgical biopsy sections of peripheral AVMs to investigate the expression pattern of integrin αvβ3 RESULTS: 68Ga-RGD PET/CT imaging showed enhanced uptake in all AVM lesions (mean SUVmax, 3.0 ± 1.1; mean SUVpeak, 2.2 ± 0.9). Lesion-to-blood and lesion-to-muscle ratios were 3.5 ± 2.2 and 4.6 ± 2.8, respectively. Uptake in blood and muscle was significantly higher in AVMs than in background tissue (P = 0.0006 and P = 0.0014, respectively). Initial observations included uptake in multifocal AVM lesions and enhanced uptake in intraosseous components in those AVM cases affecting bone integrity. Immunohistochemical analysis revealed cytoplasmatic and membranous integrin αvβ3 expression in the endothelial cells of AVMs. CONCLUSION: This feasibility study showed increased uptake in AVMs with angiogenic activity, compared with surrounding tissue without angiogenic activity, suggesting that 68Ga-RGD PET/CT imaging can be used as a tool to quantitatively determine angiogenesis in AVMs. Further studies will be conducted to explore the potential of 68Ga-RGD PET/CT imaging for guiding current treatment decisions and for assessing response to antiangiogenic treatment
Cetuximab Reduces the Accumulation of Radiolabeled Bevacizumab in Cancer Xenografts without Decreasing VEGF Expression
Bevacizumab and cetuximab are approved
for the treatment of cancer.
However, in advanced colorectal cancer, addition of cetuximab to chemotherapy
with bevacizumab did not improve survival. The reason for the lack
of activity remains unclear. The aim of this study was to determine
the effect of cetuximab on VEGF expression and targeting of bevacizumab
to the tumor. Mice with subcutaneous SUM149 or WiDr xenografts were
treated with cetuximab, bevacizumab, or a combination of the two.
Before the start of cetuximab treatment and after 7 and 21 days of
treatment, the uptake of radiolabeled bevacizumab in the tumor was
measured by immunoSPECT/CT. Tumor growth of SUM149 xenografts was
significantly inhibited by cetuximab, bevacizumab, or their combination,
whereas growth of WiDr xenografts was not affected. Cetuximab caused
a significant reduction of bevacizumab uptake in SUM149 xenografts,
whereas tumor-to-blood ratios in mice with WiDr xenografts did not
change. Biodistribution studies with an irrelevant antibody in the
SUM149 model also showed significantly reduced tumor-to-blood ratios.
Cetuximab treatment did not decrease VEGF expression. Without decreasing
VEGF levels, cetuximab reduces tumor targeting of bevacizumab. This
could, at least partly, explain why the combination of bevacizumab
and cetuximab does not result in improved therapeutic efficacy
Kaplan-Meier survival curves.
<p>Kaplan-Meier survival curve estimates of overall survival of chemotherapy (<b>A</b>) or endocrine therapy (<b>B</b>) treated patients with a tumor showing a downregulation, no change or an upregulation in IGF-1R expression after neoadjuvant treatment (p = 0.060 and p = 0.069, respectively).</p
Patient (N = 62) and tumor (N = 63) characteristics.
<p>Patient (N = 62) and tumor (N = 63) characteristics.</p
Kaplan-Meier survival curves.
<p>Kaplan-Meier survival curve estimates showing the effect of baseline IGF-1R expression (left) and changes in IGF-1R expression (right) on overall survival in the total population (<b>A</b>), and subgroup analysis in patients with non-metastatic disease (<b>B</b>) and metastatic disease (<b>C</b>).</p
Examples of IGF-1R immunostaining of breast tumors.
<p>Scoring of IGF-1R membrane expression is depicted in the lower left corner. Magnification 400X, DAB staining.</p
Immunohistochemical markers of the 63 breast tumors.
<p>Immunohistochemical markers of the 63 breast tumors.</p